BSECompany Update6d ago · 19 Oct 2026, 10:42 am
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.
Supriya Lifescience Ltd · 543434
✦ AI SummaryRegulatory
Supriya Lifescience Ltd has informed the stock exchanges that the matter related to judicial proceedings has been admitted by the Hon'ble Supreme Court and is listed for hearing. The court has directed that no coercive action shall be taken against the company's directors, officers, and officials, subject to certain conditions.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk8/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Supriya Lifescience Ltd - 543434 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
Attachments (1)
📄pdf
Download →
38ca064c-d546-4f1e-9c25-d950f6dd6d8e.pdf
View document text
October 19, 2026
BSE Limited National Stock Exchange of India
Phiroze Jeejeebhoy Towers, Limited
Dalal Street, Exchange Plaza, Plot no. C/1, G Block,
Mumbai- 400 001 Bandra-Kurla Complex
Scrip Code: 543434 Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA
Dear Sir/Madam,
Subject: Further Update on Judicial Proceedings – Intimation under Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and
in continuation to the earlier intimations made by the Company in relation to the captioned matter, we wish to
inform you that the matter has been admitted by the Hon’ble Supreme Court and is listed for hearing.
Further, the Hon’ble Supreme Court has, in the interim, directed that no coercive action shall be taken against the
Directors/officers/officials of the petitioner, subject to the terms and conditions of the order passed by the Hon’ble
Court.
The matter is presently pending before the Hon’ble Court and is sub judice. The Company shall continue to monitor
the proceedings and shall keep the Stock Exchanges and its shareholders informed of any material developments
in the matter as and when received from the Hon’ble Court or otherwise in accordance with applicable laws and
regulations.
This is for your information and records.
Thanking you,
For Supriya Lifescience Limited
Prachi Sathe
Company Secretary & Compliance Officer
Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE